CRISPR Therapeutics Stock News

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has seen a solid 26% rise over the last twenty-one trading s

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickl

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 42nd Annual Global Healthcare Broker Conference Call - (Transcript)

Unfortunately, this isn't an endorsement by a big drug developer.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $114.74, moving -0.92% from the previous trading session.

CRISPR Therapeutics AG (CRSP) CEO Sam Kulkarni Presents at Jefferies Virtual Healthcare Conference (Transcript)

CRISPR is a pioneer in the gene editing space, licensing Nobel Prize winning technology to try to treat inherited diseases, cancers, and hematological conditions. The company's lead candidate is CTX00

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

Crispr Therapeutics: Pullback Has Created Opportunity

CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstrac

One company is setting itself apart in a crowded field.

Here is what you should know about investing in these life changing technologies.